跳至主要内容
临床试验/NCT02611284
NCT02611284已完成不适用

Less Invasive Beractant Administration in Preterm Infants: a Pilot Study.

Hospital General Universitario Gregorio Marañon0 个研究点目标入组 60 人开始时间: 2013年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
主要终点
% patients >1 h of mechanical ventilation

研究概览

简要总结

The aim of this study is to assess the efficacy and feasibility of a new less invasive surfactant administration (LISA) technique with a specific designed cannula for surfactant administration using Beractant replacement in preterm infants <32 weeks of gestation and compare short and long term outcomes with the intubation, administration of surfactant and extubation method (INSURE).

This was a single-center, prospective, open-label, non-randomized, controlled study with an experimental cohort of 30 patients treated with LISA and a retrospective control group comprising the 30 most recently treated patients with INSURE. Beractant (4 ml/Kg) was administered as exogenous surfactant in both groups if patients on nasal continuous positive airway pressure (nCPAP) during the first three days of life were needed of more than 30% of fraction of inspired oxygen inspired oxygen fraction (FiO2).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
1 Minute 至 3 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Preterm infants of less than 32 weeks of gestation (WG)breathing spontaneously on nCPAP during the first three days of life that met exogenous surfactant administration criteria (Table l) were eligible to enroll in the study

排除标准

  • Infants who met intubation criteria (Table 1) at the moment of the surfactant administration were excluded in both groups.

结局指标

主要结局

% patients >1 h of mechanical ventilation

时间窗: through study completion, an average of 1 year

The percentage of patients that required more than 1 hour of mechanical ventilation during the first three days of age.

次要结局

  • need for intermittent mechanical ventilation (iMV)(through study completion, an average of 1 year)
  • second dose of surfactant(through study completion, an average of 1 year)
  • attempts to catheterize(through study completion, an average of 1 year)
  • bradycardia episodes(through study completion, an average of 1 year)
  • surfactant reflux cases(through study completion, an average of 1 year)

研究者

发起方
Hospital General Universitario Gregorio Marañon
申办方类型
Other
责任方
Principal Investigator
主要研究者

Manuel Sanchez Luna

Dr

Hospital General Universitario Gregorio Marañon

相似试验